Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | GUSB | P08236 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4285209 | 0.80 | MAPT (0.52) | NR4A2STING1 | |
| SCHEMBL1716641 | 0.80 | MAPT (0.52) | NR4A2STING1 | |
| SCHEMBL20568974 | 0.78 | STING1 (0.50) | CYP2A6NR4A2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL7539607 | 0.77 | DYRK1A (0.55) | CYP2A6NR4A2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL18642525 | 0.72 | HTR6 (0.39) | — | |
| SCHEMBL25742136 | 0.72 | NR4A2 (0.48) | CYP2A6NR4A2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL31211855 | 0.72 | MAPK1 (0.47) | — | |
| SCHEMBL29922306 | 0.72 | ACLY (0.48) | — | |
| SCHEMBL3174938 | 0.71 | NR4A2 (0.49) | CYP2A6NR4A2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL497998 | 0.71 | CYP2A6 (0.54) | CYP2A6NR4A2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130818-B2 | Transglutamine tag for efficient site-specific bioconjugation | MERCK PATENT GMBH (DE) | 2021-09-28 | — | — | US | disclosed |
| EP-3331904-B1 | A TRANSGLUTAMINE TAG FOR EFFICIENT SITE-SPECIFIC BIOCONJUGATION | MERCK PATENT GMBH (DE) | 2020-12-23 | — | — | EP | disclosed |
| US-10407482-B2 | Amino acid substituted molecules | ALLOZYNE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190194344-A1 | A TRANSGLUTAMINE TAG FOR EFFICIENT SITE-SPECIFIC BIOCONJUGATION | MERCK PATENT GMBH (DE) | 2019-06-27 | — | — | US | disclosed |
| US-10202447-B2 | Antibody derivatives | MEDIMMUNE LIMITED (GB) | 2019-02-12 | — | — | US | disclosed |
| EP-2640745-B1 | BIVALENT AND BISPECIFIC ANTI-IL6/ANTI-IL23 ANTIBODIES | MEDIMMUNE LTD (GB) | 2018-11-07 | — | — | EP | disclosed |
| EP-3331904-A1 | A TRANSGLUTAMINE TAG FOR EFFICIENT SITE-SPECIFIC BIOCONJUGATION | Merck Patent GmbH (DE) | 2018-06-13 | — | — | EP | disclosed |
| EP-2430164-B1 | PRODUCTION OF RECOMBINANT PROTEINS UTILIZING NON-ANTIBIOTIC SELECTION METHODS AND THE INCORPORATION OF NON-NATURAL AMINO ACIDS THEREIN | PFENEX INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9708616-B2 | Production of recombinant proteins utilizing non-antibiotic selection methods and the incorporation of non-natural amino acids therein | PFENEX, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2017025179-A1 | A TRANSGLUTAMINE TAG FOR EFFICIENT SITE-SPECIFIC BIOCONJUGATION | MERCK PATENT GMBH (DE) | 2017-02-16 | — | — | WO | disclosed |
| US-20100254943-A1 | AMINO ACID SUBSTITUTED MOLECULES | ALLOZYNE, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| EP-2190856-A2 | POLYPEPTIDES WITH MODIFIED AMINO ACIDS | Allozyne, Inc. (US) | 2010-06-02 | — | — | EP | disclosed |
| US-7632492-B2 | Use of host cells in forming modified target molecules, including therapeutic molecules having non-natural amino acids in their sequence; biosynthesis; drug conjugates | ALLOZYNE, INC. (US) | 2009-12-15 | — | — | US | disclosed |
| WO-2009026393-A2 | AMINO ACID SUBSTITUTED MOLECULES | ALLOZYNE, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| EP-2018437-A2 | NON-NATURAL AMINO ACID SUBSTITUTED POLYPEPTIDES | Allozyne, Inc. (US) | 2009-01-28 | — | — | EP | disclosed |
| US-20080214439-A1 | AMINO ACID SUBSTITUTED MOLECULES | ALLOZYNE, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080200641-A1 | AMINO ACID SUBSTITUTED MOLECULES | ALLOZYNE, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080125347-A1 | AMINO ACID SUBSTITUTED MOLECULES | ALLOZYNE, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080096819-A1 | Amino acid substituted molecules | ALLOZYNE, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2007130453-A2 | NON-NATURAL AMINO ACID SUBSTITUTED POLYPEPTIDES | ALLOZYNE, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130818-B2 | Transglutamine tag for efficient site-specific bioconjugation | TGM2, FOLH1, BPGM | CYP2A6 2040/4885NR4A2 4007/4885CHRNB2 3521/4885 |
| US-10407482-B2 | Amino acid substituted molecules | BCAT2, DNPEP, PTMS | CYP2A6 1758/4885NR4A2 4336/4885CHRNB2 4710/4885 |
| US-20080096819-A1 | Amino acid substituted molecules | BCAT2, DNPEP, PTMS | CYP2A6 1758/4885NR4A2 4336/4885CHRNB2 4710/4885 |
| US-20080214439-A1 | AMINO ACID SUBSTITUTED MOLECULES | BCAT2, DNPEP, PTMS | CYP2A6 1758/4885NR4A2 4336/4885CHRNB2 4710/4885 |
| US-20100254943-A1 | AMINO ACID SUBSTITUTED MOLECULES | BCAT2, DNPEP, PTMS | CYP2A6 1758/4885NR4A2 4336/4885CHRNB2 4710/4885 |
| US-10202447-B2 | Antibody derivatives | IL23R, IL6, IL2 | CYP2A6 115/4885NR4A2 4725/4885CHRNB2 4771/4885 |
| US-20080200641-A1 | AMINO ACID SUBSTITUTED MOLECULES | BCAT2, DNPEP, PTMS | CYP2A6 1758/4885NR4A2 4336/4885CHRNB2 4710/4885 |
| US-20190194344-A1 | A TRANSGLUTAMINE TAG FOR EFFICIENT SITE-SPECIFIC BIOCONJUGATION | TGM2, BPGM, FOLH1 | CYP2A6 2100/4885NR4A2 4016/4885CHRNB2 3745/4885 |
| US-20080125347-A1 | AMINO ACID SUBSTITUTED MOLECULES | BCAT2, DNPEP, PTMS | CYP2A6 1758/4885NR4A2 4336/4885CHRNB2 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.